Ethoscopes: high-throughput sleep and circadian screening platform using drosophila

Overview

This platform offers a genuinely high-throughput system for sleep and circadian phenotyping using Drosophila melanogaster, validated through publications in Nature, Nature Communications, and Science Advances. It addresses a key translational gap: botanical extracts and candidate compounds can be delivered whole in fly food, preserving natural absorption and metabolism that cell-based assays cannot replicate. The system has already been deployed at scale for industry, including a published screen of 40 treatments across 2,192 flies where a behaviour-only classifier correctly identified 39 of 40 treatments, outperforming state-of-the-art pose-estimation pipelines.

The platform serves partners seeking rigorous, mechanism-relevant sleep and circadian data without the cost or timeline of mammalian or clinical studies. A second co-funded programme with a global consumer goods partner demonstrates its applicability to sleep and wellbeing research. Fly sleep responds predictably to caffeine, antihistamines, and GABAergic hypnotics, providing direct pharmacological benchmarks against human sleep responses.

Technical specifications

Key capabilities:

• Each unit tracks 20 flies simultaneously; 100 units can run in parallel, with additional units added on demand rather than through licensing
• Units cost under GBP 100 to build, keeping infrastructure investment minimal
• Machine-learning video tracking with closed-loop feedback enables targeted, stress-free sleep deprivation
• Arousal-threshold probing and sleep-depth staging separate true sleep promotion from sedation
• Whole-fly ingestion of botanical extracts preserves absorption and metabolism that cell systems cannot model
• Readouts include sleep onset, duration, consolidation, period, and rhythm strength
• Optional integration with clock-gene reporters for mechanistic resolution
• A seven-species comparative panel supports investigation of species-specific responses, including identification of functional equivalents to mammalian circadian hormones

Validated performance:

• 39 of 40 treatments correctly classified from behaviour alone in a published 2,192-fly screen
• Drug-resistant mutant controls confirmed pharmacological signatures rather than artefacts
• Concordance demonstrated with known hypnotics, stimulants, and marketed botanicals

Technology readiness level

The platform is fully mature and operational, with continuous development since its 2017 publication. It has been validated through peer-reviewed publications in top-tier journals and through industrial deployment. A staged twelve-month engagement model is proposed, with each stage standing alone and gating the next: Stage 1 benchmarks against known sleep-active compounds; Stage 2 screens partner ingredients across concentration series with ranked shortlists; Stage 3 advances hits to circadian endpoints, phase-shift re-entrainment, and clock-gene reporters. The platform is ready for immediate deployment in sponsored research, pilot engagements, fee-for-service screening, or co-development partnerships.